"Gradual Drug Release"… Next-Generation Scar Treatment Technology Granted U.S. Patent
Joint Research Team from Bundang Seoul National University Hospital and Sookmyung Women's University Develops New Technology
Skin Regeneration and Scar Management Using MOF-808, the Nobel-winning Material
The next-generation skin regeneration technology that utilizes metal-organic frameworks (MOFs), the key material in the research that won last year's Nobel Prize in Chemistry, has been granted a patent by the U.S. Patent and Trademark Office (USPTO).
Professor Chan Young Heo (left), Plastic Surgery Department, Bundang Seoul National University Hospital, and Professor Kyung Min Choi, Department of Chemical and Biological Engineering, Sookmyung Women’s University. Bundang Seoul National University Hospital
View original imageBundang Seoul National University Hospital announced on August 21 that the "MOF-808-based scar management and skin regeneration technology," jointly developed by Professor Chanyoung Heo of the Department of Plastic Surgery at Bundang Seoul National University Hospital and Professor Kyungmin Choi of the Department of Chemical and Biological Engineering at Sookmyung Women's University, has received a notice of allowance from the USPTO.
A notice of allowance is a procedure confirming that the invention meets the legal requirements for patentability and that patent rights can be granted. The research team plans to complete the subsequent registration steps to finalize the U.S. patent. Once registration is complete, securing related intellectual property rights is expected to accelerate both technology transfer and commercialization in the future.
The core of this technology is "MOF-808," a type of metal-organic framework. MOFs are porous materials formed by combining metal ions and organic molecules, resulting in a dense network of tiny internal pores. In particular, MOF-808 features a structure where zirconium metal and organic substances are joined, enabling the internal space to store drugs and release them gradually—much like a sponge absorbs and slowly releases water. Compared to other MOFs, MOF-808 is gaining attention as a next-generation drug delivery carrier due to its high safety and biocompatibility.
The research team applied the properties of MOF-808 to the field of skin regeneration. They developed a technology that allows drugs to be stored and gradually released by incorporating MOF-808 into silicone patches and artificial skin during manufacturing. Through this approach, patches can be applied to raised hypertrophic scars to enable continuous drug delivery, thus supporting scar management and skin regeneration.
The research team initially filed a U.S. patent application for this technology in February 2024. The scope of the present patent allowance decision broadly recognizes the applicability of the technology not only to hypertrophic scars but also to various skin injuries, including chronic ulcers and post-surgical wounds.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Professor Chanyoung Heo stated, "This patent allowance is significant in that it provides a foundation for expanding MOF-808—a material attracting attention as a next-generation biomedical material—into the fields of scar management and skin regeneration. Following patent registration, we will sequentially review the potential for joint domestic and international research, technology transfer, and commercialization, aiming to develop it into a technology that can be applied in real clinical settings."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.